Previous Close | 3.9000 |
Open | 2.0000 |
Bid | 0.0000 |
Ask | 7.3000 |
Strike | 250.00 |
Expire Date | 2025-06-20 |
Day's Range | 2.0000 - 3.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 3 |
BOSTON, June 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland.
On June 3, 2024, Charles F. Wagner Jr., Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 3,250 shares of the company.
The stock market was mixed Monday, but once again closed strong. Nvidia jumped while Meta and Spotify are stocks near buy points.